Startups
Learn about KEYTRUDA® (pembrolizumab), an immunotherapy that works with your immune system to help fight certain cancers. Visit the patient website.
Overview
Location
United States
Mentions in press and media 24
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 24, 2026 | Personalized mRNA Cancer Vaccine Clears Phase 3: Melanoma Recurrence Cut by Half | By Joseph Blake Published: Aug 24 2026, 11:46 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Jul 1, 2025 | CHOSA extends the timeline for biopsy collection prior to publication from the SPLENDOUR study | CHOSA extends the timeline for biopsy collection prior to publication from the SPLENDOUR study Tue, Jul 01, 2025 16:19 CET Report this content The English text is an unofficial translation. In case of any discrepancies between the Swedish t... |
| Jun 4, 2025 | Innovent Biologics' IBI363: A New Dawn in Cancer Treatment | In the world of oncology, hope often flickers like a candle in the dark. But at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Innovent Biologics shone a bright light on the future of cancer treatment with its groundb... |
| Jun 1, 2025 | ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma | SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of... |
| May 23, 2025 | Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025 | ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-re... |
| May 13, 2025 | Finnish startup Tilt Biotherapeutics moves closer to immune-oncology breakthrough with fresh €22.6 million | Helsinki-based TILT Biotherapeutics (Tiltbio), a clinical-stage BioTech company developing intravenously delivered cancer immunotherapies, announced today it has raised €22.6 million in a Series B financing. The financing was supported by e... |
| Apr 25, 2025 | The Evolving Landscape of Oncology: Innovations and Challenges | The world of oncology is a battleground. New weapons are being forged daily, yet the fight against cancer remains daunting. Recent developments from Antengene Corporation and Gilead Sciences highlight both the promise and the pitfalls in th... |
| Apr 24, 2025 | Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025 | SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and co... |
| Mar 21, 2025 | Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up | SHANGHAI and HONG KONG, March 21, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2024, along with several significant milest... |
Show more
Reviews 0
FAQ about KEYTRUDA® (pembrolizumab)
What has the press written about KEYTRUDA® (pembrolizumab)?
Parsers VC has collected 24 articles mentioning KEYTRUDA® (pembrolizumab), among them “Personalized mRNA Cancer Vaccine Clears Phase 3: Melanoma Recurrence Cut by Half” (Aug 24, 2026) and “CHOSA extends the timeline for biopsy collection prior to publication from the SPLENDOUR study” (Jul 1, 2025).
Is KEYTRUDA® (pembrolizumab) still active?
Yes, KEYTRUDA® (pembrolizumab) is active; its latest activity on Parsers VC dates from Sep 1, 2026.